Smart Equity Invest

← Results dashboard

Q2 FY27 · NSE: ONESOURCE

Onesource Specialty Pharma

Results filed 27 October 2026 · Market cap ₹17,924 crore · PE 1566.8

GrowthGuidance maintainedTranscript read

Revenue
+37.4%
on a year ago
EBITDA
+53.3%
on a year ago
Profit to shareholders
+448.5%
on a year ago
EBITDA margin
31.6%
+4.2 pts on last quarter

OneSource reported strong Q2FY27 performance with consolidated revenue growing 37.2% YoY to ₹516 crore and EBITDA margin expanding to 31.6%, aided by the commercial startup of its second DDC line. Net profit surged 447.6% YoY to ₹57.5 crore due to operational leverage and deferred tax benefits from carried-forward losses. The company maintained its long-term FY28 target of $400 million organic revenue and $160 million reported EBITDA while noting DDC Line 3 qualification may stretch into FY28.

Onesource Specialty Pharma Limited, Q2 FY27₹ crore, consolidated
Q2 FY27Q1 FY27vs previous quarterQ2 FY26vs a year ago
Revenue516449+15.0%376+37.4%
Operating profit (EBIT)88.2451.6+71.0%36.66+140.7%
Operating margin17.1%11.5%+560 bps9.8%+734 bps
Other income0.953.8−75.0%3.04−68.8%
Exceptional items−1.77−4.3–0–
Profit before exceptional items and tax54.6324.59+122.2%5.74+851.7%
Profit to shareholders57.4825+129.9%10.48+448.5%
Earnings per share (₹)–2.18–0.92–

Source: Onesource Specialty Pharma Limited’s filing to NSE, 27 October 2026. That filing gives only the year to date, so this quarter is it less the year to date in the previous quarter’s filing. Corrected: owners' profit works out at ₹82.48 crore, which with the minority share doesn't add up to the total; used ₹57.48 crore, the total less the minority share. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.

What stood out

  • Significant margin expansion driven by operational leverage as new DDC capacity came online
    SourceEBITDA margin reached 31.6% (up 329 bps YoY, 416 bps QoQ), with EBITDA growing 53% YoY vs 37% revenue growth (Press Release, original page 7; Transcript, original page 3).
  • Delay in commercialization of third DDC cartridge line due to transit times and rigorous European vendor qualification
    SourceManagement noted arrival was delayed due to Gulf transit times and 'while we are making every effort for it to start in Q4, but the commercialization might get pushed to the start of FY28' (Transcript, original page 4).
  • Significant working capital elongation due to global shipping line delays impacting receivables cycle by 45 to 60 days
    Source'The delayed deliveries to the customer does impact at least 45 to 60 days in terms of the overall cycle time... temporary, and it is only a timing impact' (Anurag Bhagania, Transcript, original page 8).

Guidance

MetricGuidancePeriod
FY28 Organic Revenue
Source'reaffirming our FY28 outlook, which we have given of $400 million revenue' (Neeraj Sharma, Transcript, original page 5; Press Release, original page 13).
$400 millionFY28
FY28 Reported EBITDA
Source'reaffirming our FY28 outlook, which we have given of... $160 million EBITDA' and confirmed it is reported EBITDA (Transcript, original pages 5, 15; Press Release, original page 13).
$160 million (steady state margin ~40%)FY28
Debt / Leverage
Source'we anticipate we will continue to remain under 1.5x EBITDA margin in terms of our debt levels' (Anurag Bhagania, Transcript, original page 14).
Under 1.5x EBITDAFY28
ROCE
Source'by end of FY28, we should be in high 20s in terms of our ROCE returns' (Anurag Bhagania, Transcript, original page 14).
High 20s (%)By end of FY28
Effective Tax Rate (ETR)
Source'current level of ETRs will continue through till FY28, at least till the third quarter of FY28' due to brought forward losses (Anurag Bhagania, Transcript, original page 11).
Current low level to continue due to brought-forward lossesThrough Q3FY28

Maintained FY28 guidance of $400m organic revenue and $160m EBITDA (~40% margin).

Tailwinds

  • Operationalization of second DDC cartridge line in September doubled sterile production days and allowed higher MSA execution
    Source'the line already since September, it is operational, and it has immediately doubled our total sterile production days... supports both the new launches which are coming in and provide us a significant ramp-up of the commercial volumes' (Neeraj Sharma, Transcript, original page 4).
  • Geographic expansion of semaglutide with partner launches and key customer approvals
    Source'our partner, Hikma, launched the first generic semaglutide in Saudi Arabia... Dr. Reddy's API has commenced... help relaunch in Canada as well as launch across multiple other markets' (Neeraj Sharma, Transcript, original page 4).
  • High operating leverage delivering 53% YoY and 32% QoQ EBITDA growth
    SourceEBITDA grew faster than revenue due to limited incremental opex vs incremental revenue (Transcript, original pages 3, 10; Press Release, original page 7).

Headwinds

  • Geopolitical issues and shipping bottlenecks affecting transit times and working capital cycle
    SourceDelayed deliveries impacted cash cycle by 45-60 days and pushed transit times in the Gulf for equipment (Anurag Bhagania, Transcript, original page 8).
  • Planned site shutdown for injectables capacity expansion impacting revenue in Q2 and Q3
    Source'the shutdown started only at the back end of the quarter ending September. And the shutdown will last this current quarter' (Neeraj Sharma, Transcript, original page 6).

New businesses and products

capacity expansion · Factory acceptance test completed in Germany; line at site ready for qualification

Third DDC Cartridge Line (500L+ batch size)

Expected benefit
Tripling total DDC capacity by FY28 to run 500-liter or larger batches
Risks
Extended qualification involving multiple European vendors pushing commercialization from Q4FY27 to start of FY28; transit disruption
Timeline
Start of FY28 (or Q4FY27 best effort)
SourceTranscript, original pages 4, 6, 7

capacity expansion · Planned shutdown initiated in late Q2FY27, continuing through current quarter

Injectables Lyophilization and Prefilled Syringe (PFS) Expansion

Expected benefit
Significantly increases lyophilization capacity and capability to address global drug shortages
Risks
Plant downtime during shutdown
Timeline
Available starting January (Q4FY27)
SourceTranscript, original pages 5, 6

capacity expansion · Planned / entering setup phase as current facility reaches capacity limits

New Greenfield Softgel Facility

Expected benefit
Enables expansion into high potent softgels and containment where existing site lacks space
Risks
Execution and ramp-up cycle times
SourceTranscript, original pages 6, 7

new business · Signed/onboarded during Q2FY27

US Biopharma Partnership for Biologics

Expected benefit
Two end-to-end DS + DP development to commercialization projects
Timeline
R&D/MSA phase during guidance period; commercial revenues from FY29 onwards
SourcePress Release, original page 11; Transcript, original pages 4, 13

Things to check

  • Profit grew far faster than operating profit: other income, tax or one-offs did some of the work
  • Trade receivables elongation of 45-60 days due to shipping disruptions and shipment back-loading
    SourceCFO noted delayed deliveries to customers have lengthened cycle times by 45 to 60 days (Transcript, original page 8).
  • Operational delay on bespoke DDC Line 3 qualification
    SourceCommercialization originally planned for Q4FY27 is likely deferred to FY28 due to Gulf transit and vendor qualification requirements (Transcript, original page 4).

How the call went

The call was informative with good technical granularity regarding plant operations, batch sizes, and future commercial line capacities, while remaining guarded on proprietary client/molecule details.

Specific or vague
Management provided detailed metrics on batch capacities (200L ramping to 500L/750L), annual sterile days (225-230 days), and capacity utilization visibility (80%+ in softgel), although product-specific pricing and exact customer splits were omitted.
Candour
Management openly disclosed potential qualification slippages into FY28 for Line 3, transit delays in the Gulf, and 45-60 day elongations in receivable collection cycles.
The hard questions
Analysts probed into batch efficiency differences between Line 1 and Line 2, working capital elongation, and specific exposure to molecules like Keytruda biosimilars.

What analysts pressed on

  • Working capital elongation and increase in trade receivables during H1FY27.
  • Timeline and commercialization risk of DDC Line 3.
  • Sequential impact of the Steriscience site shutdown in injectables during Q2 and Q3.
  • Sustainability of realizations as volume shifts to emerging markets.

Answers that sidestepped

  • Deflected questions on participation in specific biosimilar molecules such as Keytruda citing confidentiality (Transcript, original page 7).
  • Avoided providing the exact Q2 revenue breakdown/ratio between MSA and CSA for DDC, pointing to steady-state estimates instead (Transcript, original page 14).

Numbers against the story

Reported net profit increased 448% YoY (from ₹10.5 crore to ₹57.5 crore), vastly outpacing EBITDA growth (+53% YoY). The narrative and notes clarify that this is largely due to low effective tax rates supported by brought forward tax losses, along with amortisation adjustments. Revenue and EBITDA operating performance matched management's guidance of operating leverage driven by DDC Line 2 commercialization.

Sources

Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.